{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_52929"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_52929","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"MECHANISMS AND THERAPEUTIC INTERVENTIONS IN TREATMENT-RESISTANT KEAP1-MUTANT LUNG ADENOCARCINOMA","abstract":"Thesis (Ph.D.)--Michigan State University. Pharmacology and Toxicology - Doctor of Philosophy, 2026","abstract_html":"Thesis (Ph.D.)--Michigan State University. Pharmacology and Toxicology - Doctor of Philosophy, 2026","abstract_has_math":false,"creators":["Occhiuto, Christopher J"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Neubig, Richard","Bernard, Jamie","MacKeigan, Jeffrey","Rockwell, Cheryl"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T18:59:31Z","subjects":["Oncology","Pharmacology"],"languages":["eng"],"rights":["Attribution-NonCommercial 4.0 International"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:52929","local:Occhiuto_grad.msu_0128D_21933"],"render_values":[{"text":"etd:52929","href":null,"code":true},{"text":"local:Occhiuto_grad.msu_0128D_21933","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/atwc-w256","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/atwc-w256","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_52929","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Neubig, Richard","Bernard, Jamie","MacKeigan, Jeffrey","Rockwell, Cheryl"]},{"key":"dc:creator","label":"Author","values":["Occhiuto, Christopher J"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2026"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["text","Electronic dissertations"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Oncology","Pharmacology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution-NonCommercial 4.0 International"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:52929","local:Occhiuto_grad.msu_0128D_21933","https://doi.org/doi:10.25335/atwc-w256"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (Ph.D.)--Michigan State University. Pharmacology and Toxicology - Doctor of Philosophy, 2026","Lung adenocarcinoma remains one of the most lethal cancers, with poor survival driven by therapy resistance and immune evasion. Tumors with KEAP1 mutations represent a particularly difficult subset. KEAP1 normally restrains the NRF2 oxidative stress pathway, and its loss leads to constitutive NRF2 activation. This promotes metabolic flexibility, chemoresistance, and a strongly immunosuppressive tumor environment. This dissertation investigates how mutant KEAP1 and sustained NRF2 activity drive immune evasion and evaluates strategies to overcome resistance in non-small cell lung cancer. We first outline the dual and context-dependent role of NRF2 in carcinogenesis. NRF2 protects normal cells from oxidative damage and limits malignant transformation. In contrast, cancer cells with persistent NRF2 activity gain enhanced survival, stress tolerance, and metastatic capacity. Within immune cells, however, NRF2 activation can support anti-tumor responses. Using CRISPR-engineered murine lung cancer models, we characterized the immune microenvironment of KEAP1 knockout tumors. Loss of KEAP1 produced a distinctly immunosuppressive phenotype with reduced pro-inflammatory signaling, elevated immune checkpoint expression, and recruitment of myeloid cells. These changes were accompanied by weakened CD8 T-cell activation and enrichment of M2-like macrophages. To counteract these effects, we evaluated two therapeutic strategies. The first used systemic triterpenoid treatment with the NRF2 activators CDDO-Me and omaveloxolone. These agents suppressed tumor growth, shifted macrophages toward an anti-tumor state, and enhanced interferon signaling in a manner that did not depend on tumor KEAP1 status. The second strategy targeted pathways identified through transcriptomic profiling. KEAP1-mutant tumors showed upregulation of arachidonic acid metabolism and the COX-2/PGE2 axis, along with reduced interferon-related gene expression. Inhibition of this pathway with celecoxib increased interferon signaling, supported anti-tumor macrophage function, promoted immune hot niches within the tumor, and selectively slowed growth of KEAP1-mutant tumors. Together, this work shows how KEAP1 mutations and persistent NRF2 activity reshape lung cancer metabolism, immunity, and therapeutic response. It also identifies prostaglandin-driven immune suppression as a central vulnerability and highlights two strategies that restore anti-tumor immunity in treatment-resistant lung cancer.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf","1 online resource (250 p.) : ill."]},{"key":"dc:title","label":"Title","values":["MECHANISMS AND THERAPEUTIC INTERVENTIONS IN TREATMENT-RESISTANT KEAP1-MUTANT LUNG ADENOCARCINOMA"]}]}],"canonical_facts":{"dc:contributor":["Neubig, Richard","Bernard, Jamie","MacKeigan, Jeffrey","Rockwell, Cheryl"],"dc:creator":["Occhiuto, Christopher J"],"dc:date":["2026"],"dc:description":["Thesis (Ph.D.)--Michigan State University. Pharmacology and Toxicology - Doctor of Philosophy, 2026","Lung adenocarcinoma remains one of the most lethal cancers, with poor survival driven by therapy resistance and immune evasion. Tumors with KEAP1 mutations represent a particularly difficult subset. KEAP1 normally restrains the NRF2 oxidative stress pathway, and its loss leads to constitutive NRF2 activation. This promotes metabolic flexibility, chemoresistance, and a strongly immunosuppressive tumor environment. This dissertation investigates how mutant KEAP1 and sustained NRF2 activity drive immune evasion and evaluates strategies to overcome resistance in non-small cell lung cancer. We first outline the dual and context-dependent role of NRF2 in carcinogenesis. NRF2 protects normal cells from oxidative damage and limits malignant transformation. In contrast, cancer cells with persistent NRF2 activity gain enhanced survival, stress tolerance, and metastatic capacity. Within immune cells, however, NRF2 activation can support anti-tumor responses. Using CRISPR-engineered murine lung cancer models, we characterized the immune microenvironment of KEAP1 knockout tumors. Loss of KEAP1 produced a distinctly immunosuppressive phenotype with reduced pro-inflammatory signaling, elevated immune checkpoint expression, and recruitment of myeloid cells. These changes were accompanied by weakened CD8 T-cell activation and enrichment of M2-like macrophages. To counteract these effects, we evaluated two therapeutic strategies. The first used systemic triterpenoid treatment with the NRF2 activators CDDO-Me and omaveloxolone. These agents suppressed tumor growth, shifted macrophages toward an anti-tumor state, and enhanced interferon signaling in a manner that did not depend on tumor KEAP1 status. The second strategy targeted pathways identified through transcriptomic profiling. KEAP1-mutant tumors showed upregulation of arachidonic acid metabolism and the COX-2/PGE2 axis, along with reduced interferon-related gene expression. Inhibition of this pathway with celecoxib increased interferon signaling, supported anti-tumor macrophage function, promoted immune hot niches within the tumor, and selectively slowed growth of KEAP1-mutant tumors. Together, this work shows how KEAP1 mutations and persistent NRF2 activity reshape lung cancer metabolism, immunity, and therapeutic response. It also identifies prostaglandin-driven immune suppression as a central vulnerability and highlights two strategies that restore anti-tumor immunity in treatment-resistant lung cancer.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."],"dc:format":["application/pdf","1 online resource (250 p.) : ill."],"dc:identifier":["etd:52929","local:Occhiuto_grad.msu_0128D_21933","https://doi.org/doi:10.25335/atwc-w256"],"dc:language":["eng"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["Attribution-NonCommercial 4.0 International"],"dc:subject":["Oncology","Pharmacology"],"dc:title":["MECHANISMS AND THERAPEUTIC INTERVENTIONS IN TREATMENT-RESISTANT KEAP1-MUTANT LUNG ADENOCARCINOMA"],"dc:type":["text","Electronic dissertations"]},"updated_at":"2026-11-18T18:59:31Z"}